AI and Blood Metabolites Could Revolutionize Early Diabetes Detection

Type 2 diabetes affects over one in nine adults worldwide, with more than 90% of cases falling into this category. The condition often develops slowly and without clear symptoms, making early detection a major challenge. Now, researchers are exploring how blood metabolites and artificial intelligence could improve risk prediction and prevention.

Current tools for assessing diabetes risk rely on factors like age, weight, family history, and blood sugar levels. However, these methods may miss early biological changes that signal future problems. Scientists have found that diet and lifestyle influence metabolites linked to type 2 diabetes more strongly than those unrelated to the condition.

Metabolites—small molecules in the blood—can reveal early dysfunctions in how the body processes sugar, fats, and energy. A combination of these metabolites provides a better prediction of future diabetes risk than any single marker. This approach could help identify at-risk individuals before symptoms appear. An AI model called GluFormer has shown promise in detecting high-risk patients. In one study, 66% of participants flagged as high-risk by GluFormer later developed diabetes, compared to just 7% in the lowest-risk group. The model also outperformed the standard HbA1c blood test in predicting both diabetes and cardiovascular death risk. Early diagnosis is critical because, by the time type 2 diabetes is confirmed, it may have already damaged the heart, kidneys, or blood vessels. Understanding these underlying mechanisms could lead to more targeted prevention strategies and new treatments.

The use of AI and metabolite analysis offers a clearer way to assess diabetes risk before irreversible harm occurs. With better prediction tools, healthcare providers could intervene earlier, potentially reducing complications and improving long-term outcomes. This research may also pave the way for more personalised prevention plans in the future.